InterMune (ITMN) Ratings, Price Targets

InterMune (NASDAQ: ITMN) ratings and price targets.

Canaccord Genuity reiterated its "Buy" rating on InterMune today.

Goldman Sachs (NYSE: GS) reiterated its ratings on InterMune. They have a "Neutral" rating on the company.

Oppenheimer (NYSE: OPY) recently lowered its price target on InterMune to $38.00.

InterMune was trading at $15.24, gaining $0.73, or 5.03 percent, as of 11:46 AM EST.

InterMune (ITMN) (IPSU) (DEER) (AMPE) (ATHN) (OCC) Biggest NASDAQ Losers

InterMune, Inc. (NASDAQ:ITMN), Imperial Sugar Co. (NASDAQ:IPSU), Deer Consumer Products, Inc. (NASDAQ:DEER), Ampio Pharmaceutical (NASDAQ:AMPE), AthenaHealth (NASDAQ:ATHN) and Optical Cable Corp. (NASDAQ:OCC) were the biggest losers on the NASDAQ, Thursday, December 15.

InterMune, Inc. (ITMN) ended the session down 29.80 percent, closing at $12.84. They traded in a range of $12.52 to $18.35. A total of 18,411,423 shares changed hands.

Imperial Sugar Co. (IPSU) ended the session down 24.37 percent, closing at $3.29. They traded in a range of $3.14 to $4.17. A total of 1,248,884 shares changed hands.

Deer Consumer Products, Inc. (DEER) ended the session down 24.03 percent, closing at $3.73. They traded in a range of $3.58 to $4.95. A total of 124,804 shares changed hands.

Ampio Pharmaceutical (AMPE) ended the session down 22.17 percent, closing at $4.67. They traded in a range of $3.60 to $6.41. A total of 293,118 shares changed hands.

AthenaHealth (ATHN) ended the session down 16.44 percent, closing at $48.49. They traded in a range of $40.79 to $58.99. A total of 9,975,558 shares changed hands.

Optical Cable Corp. (OCC) ended the session down 15.83 percent, closing at $3.03. They traded in a range of $3.00 to $3.27. A total of 13,902 shares changed hands.

InterMune (NASDAQ:ITMN) Continues Surge on Esbriet

Shares of InterMune Inc. (NASDAQ:ITMN) continue to rise on the news of the positive response from European authorities on Esbriet, ITMN’s drug for Idiopathic Pulmonary Fibrosis.

Canaccord said, "Last week, Esbriet, ITMN’s drug for Idiopathic Pulmonary Fibrosis (IPF) was given a positive opinion by the European regulatory agency based on a good benefit to risk balance.”

All of this is predicated on the probability they'll be able to commercialize Esbriet in Europe and elsewhere.

Canaccord Genuity maintains a "Buy" on InterMune Inc., which closed Monday at $35.81, up $0.92, or 2.64 percent. Canaccord has a price target of $43 on them.